Does Dolutegravir Sodium And Lamivudine Interact with Dofetilide?
Dolutegravir Sodium And Lamivudine and Dofetilide have a major drug interaction according to U.S. FDA drug labeling data. Dolutegravir inhibits renal OCT2 and MATE1 transporters, which may increase plasma concentrations of dofetilide. The mechanism involves inhibition of oct2 and mate1 transporters. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Dolutegravir Sodium And Lamivudine Class
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
- Dofetilide Class
- Antiarrhythmic
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Dolutegravir Sodium And Lamivudine and Dofetilide occurs because inhibition of oct2 and mate1 transporters. Clinically, this means dolutegravir inhibits renal oct2 and mate1 transporters, which may increase plasma concentrations of dofetilide. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Dolutegravir Sodium And Lamivudine and your doctor is considering prescribing Dofetilide (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider